Salibee
2021-05-17
@LoneSurvivor
pls reply to this comment i beg you
UPDATE 1-U.S. Supreme Court rejects J&J appeal over Risperdal drug
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":195198428,"tweetId":"195198428","gmtCreate":1621260826764,"gmtModify":1634192951635,"author":{"id":3578610877384773,"idStr":"3578610877384773","authorId":3578610877384773,"authorIdStr":"3578610877384773","name":"Salibee","avatar":"https://static.tigerbbs.com/4171df5071ff91dad108e551fca14644","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/U/3579266597292844\">@LoneSurvivor</a>pls reply to this comment i beg you</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/U/3579266597292844\">@LoneSurvivor</a>pls reply to this comment i beg you</p></body></html>","text":"@LoneSurvivorpls reply to this comment i beg you","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/195198428","repostId":2136953639,"repostType":2,"repost":{"id":"2136953639","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1621260027,"share":"https://www.laohu8.com/m/news/2136953639?lang=&edition=full","pubTime":"2021-05-17 22:00","market":"us","language":"en","title":"UPDATE 1-U.S. Supreme Court rejects J&J appeal over Risperdal drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2136953639","media":"Reuters","summary":"(Adds background on case) By Lawrence Hurley WASHINGTON, May 17 (Reuters) - The U.S. Supreme Cou","content":"<html><body><p>(Adds background on case)</p><p> By Lawrence Hurley</p><p> WASHINGTON, May 17 (Reuters) - The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal.</p><p> The court turned away the company's appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. </p><p> A jury in the Philadelphia Court of Common Pleas in 2016 found that the company failed to warn Yount's healthcare providers about the risk of gynecomastia, an enlargement or swelling of breast tissue in males caused by a hormonal imbalance, and that it intentionally falsified, destroyed or concealed evidence in the case.</p><p> Warnings contained on drug labels are overseen by the U.S. Food and Drug Administration. But \"off-label\" uses - to treat patient populations outside of the FDA's approval or for conditions and dosage beyond the agency's approval - by doctors are commonplace.</p><p> Yount developed gynecomastia at age 5 as a result of taking Risperdal, according to his lawyers. J&J has said that Yount's doctor discontinued the treatment but that the patient's mother requested that it be resumed. The drug at the time had not been approved for pediatric use so the label did not include a specific warning about gynecomastia in children.</p><p> J&J's lawyers have said the verdict was impermissible under federal law. It said it could not have included the warning because manufacturers are barred from changing their labels to include information about off-label uses.</p><p> The FDA approved Risperdal in 1993 to treat schizophrenia and bipolar mania in adults, but it was only in 2006 that its use was approved for irritability associated with autism in children.</p><p> New Brunswick, New Jersey-based J&J and its Janssen Pharmaceuticals unit have faced thousands of Risperdal-related lawsuits and 10,000 remain pending, according to the company. One case resulted in an initial $8 billion jury verdict, which was later reduced to $6.8 million.</p><p> The company agreed separately in 2013 to pay $2.2 billion to settle U.S. criminal and civil probes into its marketing of Risperdal and two other drugs.</p><p> (Reporting by Lawrence Hurley; Editing by Will Dunham)</p><p>((lawrence.hurley@thomsonreuters.com; <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>: @lawrencehurley; +1 202-809-3080;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-U.S. Supreme Court rejects J&J appeal over Risperdal drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-U.S. Supreme Court rejects J&J appeal over Risperdal drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-17 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds background on case)</p><p> By Lawrence Hurley</p><p> WASHINGTON, May 17 (Reuters) - The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal.</p><p> The court turned away the company's appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. </p><p> A jury in the Philadelphia Court of Common Pleas in 2016 found that the company failed to warn Yount's healthcare providers about the risk of gynecomastia, an enlargement or swelling of breast tissue in males caused by a hormonal imbalance, and that it intentionally falsified, destroyed or concealed evidence in the case.</p><p> Warnings contained on drug labels are overseen by the U.S. Food and Drug Administration. But \"off-label\" uses - to treat patient populations outside of the FDA's approval or for conditions and dosage beyond the agency's approval - by doctors are commonplace.</p><p> Yount developed gynecomastia at age 5 as a result of taking Risperdal, according to his lawyers. J&J has said that Yount's doctor discontinued the treatment but that the patient's mother requested that it be resumed. The drug at the time had not been approved for pediatric use so the label did not include a specific warning about gynecomastia in children.</p><p> J&J's lawyers have said the verdict was impermissible under federal law. It said it could not have included the warning because manufacturers are barred from changing their labels to include information about off-label uses.</p><p> The FDA approved Risperdal in 1993 to treat schizophrenia and bipolar mania in adults, but it was only in 2006 that its use was approved for irritability associated with autism in children.</p><p> New Brunswick, New Jersey-based J&J and its Janssen Pharmaceuticals unit have faced thousands of Risperdal-related lawsuits and 10,000 remain pending, according to the company. One case resulted in an initial $8 billion jury verdict, which was later reduced to $6.8 million.</p><p> The company agreed separately in 2013 to pay $2.2 billion to settle U.S. criminal and civil probes into its marketing of Risperdal and two other drugs.</p><p> (Reporting by Lawrence Hurley; Editing by Will Dunham)</p><p>((lawrence.hurley@thomsonreuters.com; <a href=\"https://laohu8.com/S/TWTR\">Twitter</a>: @lawrencehurley; +1 202-809-3080;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136953639","content_text":"(Adds background on case) By Lawrence Hurley WASHINGTON, May 17 (Reuters) - The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal. The court turned away the company's appeal of a November 2019 ruling by the Superior Court of Pennsylvania that upheld the verdict in favor of a Tennessee man named Adam Yount, who was prescribed the drug at age 4 in 2003. A jury in the Philadelphia Court of Common Pleas in 2016 found that the company failed to warn Yount's healthcare providers about the risk of gynecomastia, an enlargement or swelling of breast tissue in males caused by a hormonal imbalance, and that it intentionally falsified, destroyed or concealed evidence in the case. Warnings contained on drug labels are overseen by the U.S. Food and Drug Administration. But \"off-label\" uses - to treat patient populations outside of the FDA's approval or for conditions and dosage beyond the agency's approval - by doctors are commonplace. Yount developed gynecomastia at age 5 as a result of taking Risperdal, according to his lawyers. J&J has said that Yount's doctor discontinued the treatment but that the patient's mother requested that it be resumed. The drug at the time had not been approved for pediatric use so the label did not include a specific warning about gynecomastia in children. J&J's lawyers have said the verdict was impermissible under federal law. It said it could not have included the warning because manufacturers are barred from changing their labels to include information about off-label uses. The FDA approved Risperdal in 1993 to treat schizophrenia and bipolar mania in adults, but it was only in 2006 that its use was approved for irritability associated with autism in children. New Brunswick, New Jersey-based J&J and its Janssen Pharmaceuticals unit have faced thousands of Risperdal-related lawsuits and 10,000 remain pending, according to the company. One case resulted in an initial $8 billion jury verdict, which was later reduced to $6.8 million. The company agreed separately in 2013 to pay $2.2 billion to settle U.S. criminal and civil probes into its marketing of Risperdal and two other drugs. (Reporting by Lawrence Hurley; Editing by Will Dunham)((lawrence.hurley@thomsonreuters.com; Twitter: @lawrencehurley; +1 202-809-3080;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":109,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/195198428"}
精彩评论